Pfizer and Bristol-Myers Squibb’s next-gen anticoagulant Eliquis grabbed a commanding lead over its competitors—even topping longtime U.S. market leader warfarin. Not content to rest on its laurels, the alliance is now touting a new round of real-world data that could boost its use against older go-to meds in Europe.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,